PPAR ligands: potential therapies for metabolic syndrome (Q36016948)

11 August 2017

1 reference

title

PPAR ligands: potential therapies for metabolic syndrome (English)

1 reference

11 August 2017

1 reference

Taro E Akiyama

1

1 reference

11 August 2017

Peter T Meinke

series ordinal

2

1 reference

11 August 2017

Joel P Berger

series ordinal

3

1 reference

11 August 2017

1 February 2005

1 reference

11 August 2017

Current diabetes report

1 reference

11 August 2017

5

1 reference

11 August 2017

1

1 reference

11 August 2017

45-52

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-005-0067-3

11 August 2017

0 references

cites work

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-005-0067-3

Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more....

21 January 2018

1 reference

12 December 2020

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

1 reference

12 December 2020

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

1 reference

12 December 2020

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

1 reference

12 December 2020

Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

1 reference

12 December 2020

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

1 reference

12 December 2020

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

1 reference

12 December 2020

Critical roles of PPAR beta/delta in keratinocyte response to inflammation

1 reference

12 December 2020

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

12 December 2020

Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system

1 reference

12 December 2020

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

1 reference

12 December 2020

Benzoyl 2-methyl indoles as selective PPARgamma modulators

1 reference

12 December 2020

Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma in diabetes and metabolism

1 reference

12 December 2020

Treating lipid abnormalities in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Lessons from the glitazones: a story of drug development

1 reference

12 December 2020

1 reference

12 December 2020

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

12 December 2020

Regulation of muscle fiber type and running endurance by PPARdelta

1 reference

12 December 2020

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones

1 reference

12 December 2020

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

12 December 2020

PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy

1 reference

12 December 2020

PPAR gamma and the control of adipogenesis

1 reference

12 December 2020

11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease

1 reference

12 December 2020

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

1 reference

12 December 2020

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

12 December 2020

Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.

1 reference

12 December 2020

Inflammation and atherosclerosis

1 reference

12 December 2020

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

12 December 2020

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

12 December 2020

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

12 December 2020

Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism

1 reference

12 December 2020

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

1 reference

12 December 2020

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

1 reference

12 December 2020

Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes

1 reference

12 December 2020

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis.

1 reference

12 December 2020

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

1 reference

12 December 2020

PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion.

1 reference

12 December 2020

Hypertension and the metabolic syndrome

1 reference

12 December 2020

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

12 December 2020

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

12 December 2020

An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity

1 reference

12 December 2020

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

1 reference

12 December 2020

Emerging concepts in metabolic abnormalities associated with coronary artery disease

1 reference

12 December 2020

Considerations for management of fluid dynamic issues associated with thiazolidinediones

1 reference

12 December 2020

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

12 December 2020

Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease

1 reference

12 December 2020

Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers

1 reference

12 December 2020

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

12 December 2020

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

1 reference

12 December 2020

Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.

1 reference

12 December 2020

A transgenic model of visceral obesity and the metabolic syndrome

1 reference

12 December 2020

Clinical interest of PPARs ligands

1 reference

12 December 2020

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

12 December 2020

The mechanisms of action of PPARs

1 reference

12 December 2020

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease

1 reference

12 December 2020

Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells

1 reference

12 December 2020

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

1 reference

12 December 2020

Peroxisome proliferator-activated receptor γ in diabetes and metabolism

1 reference

12 December 2020

10.1007/S11892-005-0067-3

Identifiers

DOI

1 reference

release_oovigif3urej3bsbvs5nzrxvni

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oovigif3urej3bsbvs5nzrxvni

24 November 2022

mapped directly with Wikidata item

1 reference